碳酸镧治疗腹膜透析患者顽固性高磷血症的临床分析  

Clinical anaiysis of lanthanum carbonate in the treatment of refractory hyperphosphatemia in peritoneal dialysis patients

作　　者：付畅[1] 金弢[1] 董庆泽 熊焰[1] 

机构地区：[1]沈阳市红十字会医院肾内科,辽宁沈阳110013

出　　处：《中国医学工程》2015年第2期23-24,共2页China Medical Engineering

摘　　要：目的观察碳酸镧治疗腹膜透析患者顽固性高磷血症的有效性和安全性。方法 15例顽固性高磷血症的腹膜透析患者,每日三餐均嚼服碳酸镧咀嚼片500 mg,6周后对血磷水平进行分析评估,观察不良反应。结果 15例患者治疗6周后血磷由(2.96±0.31)mmol/L降为(1.92±0.37)mmol/L(P<0.05),血钙和甲状旁腺素水平治疗前后无明显变化,且无严重不良反应。结论短期服用碳酸镧可以有效、安全的降低腹膜透析患者血磷水平。[ Objective ] To assess the efficacy and side effects of lanthanum carbonate in peritoneal dialysis patients with refractory hyperphosphatemia. [ Methods ] Fifteen peritoneal dialysis patients with refractory hyperphosphatemia were prescribed with lanthanum carbonate 500 mg for six weeks,three times a day in mealtime.The serum phosphorus was examined before and after treatment and the side effects was also observed. [ Results ] After treatment,serum phosphorus decreased significantly from（2.96 ± 0.31）mmol/L to （1.92 ± 0.37）mmol/L（P〈0.05）,The serum calcium and serum parathyroid hormone show no obvious variation（P〉0.05）.The side effects of lanthanum carbonate were weak,only three patients feel sick to there stomach.No patient interrupted therapy and no serious adverse events were observed. [ Conclusion ] The management of hyperphosphatemia with lanthanum carbonate in peritoneal dialysis patients is safe and effective.

关 键 词：碳酸镧 顽固性高磷血症 腹膜透析 

分 类 号：R559[医药卫生—血液循环系统疾病]